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Abstract A full-length cDNA coding for human lactoferrin was 
isolated from a mammary gland library and the recombinant 
protein was expressed in BHK cells as described by Stoweli K.M. 
et al. [1991, Biochem. J. 276, 349-355[. Two N-linked glycans 
from purified recombinant lactoferrin were released by hy- 
drazinolysis and analyzed by 400-MHz ~H-NMR spectroscopy. 
The identified structures corresponded to N-acetyllactosaminic 
biantennary glycans and were ~-2,3-disialylated forms (80%) or 
a-2,3-monosialylated (20%) forms. Moreover, 70% of total gly- 
cans were ~-l,6-fucosylated at the GIcNAc residue linked to 
asparagine. In regard to its glycan moiety, the recombinant 
glycoprotein is close to native lactoferrins from milk or leucocytes 
but shows specific structural features which should be taken into 
account prior to in vivo and in vitro biological studies. 
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1. Introduction 
Human lactoferrin (or lactotransferrin) (hLf) is a 80 kDa 
bilobed glycoprotein of the transferrin class which is found in 
secretions, mainly in milk [1], and is also present in neutrophilic 
leucocytes [2]. No significant differences between milk and leu- 
cocyte hLfs have been reported with respect to the protein 
moiety [3] but the two N-acetyllactosaminic glycans of the mol- 
ecules are different [4,5]. Milk hLf  glycans differ from those of 
the leucocyte protein by the presence of c~-1,6 and ~-1,3 fucose 
residues and by the degree of sialylation [4,5]. Since the only 
specific structural features of hLfs from various tissues concern 
the nature of the carbohydrate chains, the question of the 
influence of the glycan moiety on the biological activities o fhL f  
can be raised. In particular, it can be assumed that the clearance 
of hLf  in the organism or its distribution on cells or tissues is 
mediated through carbohydrate recognition systems. The bind- 
ing of milk hLf to monkey enterocytes [6], rat hepatocytes [7,8] 
and human macrophages [9], essentially through fucose-bind- 
ing membrane lectins, has been reported. This binding proba- 
bly does not occur for leucocyte hLf since the molecule is not 
fucosylated [5]. 
Expression of cloned hLf [10] and of its N-terminal half [11] 
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in BHK cells has been previously performed to undertake struc- 
tural, functional and biological studies. Recombinant hLf was 
shown to be N-glycosylated but the structure of the glycans was 
not determined [10]. 
Since the definition of the glycosylation pattern of a recombi- 
nant protein is of importance for biological studies, we have 
cloned hLf and produced the recombinant protein in BHK 
cells. We have resolved the complete structure of two glycans 
of the recombinant protein using 400-MHz ~H-NMR spectros- 
copy. 
2. Materials and methods 
2.1. Materials 
All restriction endonucleases and nucleotides were obtained from 
Eurogentec (Seraing, Belgium). T4 ligase and T4 polynucleotide kinase 
were from Stratagene (La Jolla, USA). pcDNAI/neo was obtained from 
lnvitrogen (San Diego, USA). Dulbecco's modified essential medium 
(DMEM), DMEM-F12 nutrient mixture, foetal-calf serum (FCS), U1- 
troser-G, gentamicin and geneticin G-418 were from Gibco BRL 
(France). Methotrexate (MTX) was from ICN Biomedical (Aurora, 
USA). SP-Sepharose Fast Flow was from Pharmacia Biotech (St- 
Quentin-Yvelines, France) and BioGel P2 was from Bio-Rad Laborato- 
ries (Richmond, CA, USA). D20 (99.95 atom % D) was from the 
Commissariat/i l'Energie Atomique (Saclay, France). Hydrazine, acetic 
anhydride, sodium acetate, copper acetate and N+O columns ets were 
from Oxford GlycoSystems (Abingdon, UK). All other reagents were 
analytical grade or purer. 
2.2. Isolation of hLf cDNA and vector construction 
A human mammary gland cDNA library constructed in the Agtl 1 
vector (CIontech, Palo Alto, USA) was screened with a synthetic ol- 
igonucleotide corresponding to nucleotides 293-317 of hLf cDNA 
(numbered according to [12]) as a hybridization probe and a positive 
clone was isolated and sequenced. Due to the presence of an EcoRI 
restriction site at position 2,413 in the coding sequence of the hLf 
cDNA [12], a full-length 2.3 kb cDNA was excised from Agtl I using 
mild EeoRI hydrolysis conditions (3 U enzyme//,~g DNA for 2 min at 
37°C) and subcloned into the EcoRl site ofpBluescript SK (Stratagene, 
La Jolla, USA). The resulting plasmid was then digested with XbaI and 
HindIII and the XbaIlHindlII 2.3 kb fragment, made blunt-ended, was 
subcloned into the SmaI site of the expression vector pNUT (generously 
provided by Dr. R. Palmiter [13]) to yield pNUT-hLf. 
2.3. Cell culture, transfection and expression 
Baby hamster kidney cells (BHK) kindly provided by Dr. L. Mon- 
tagn6 (Institut Pasteur, Paris, France) were maintained on DMEM with 
10% (v/v) foetal-calf serum and gentamicin (50,ug/ml) (DME/FCS) at 
37°C and 5% CO2 air environment. BHK cells were cotransfected both 
with pcDNAl/neo and pNUT-hLf in a ratio of 1/20 by the conventional 
calcium phosphate technique [14]. For selection of stable transfectants, 
cells were first cultured in DME/FCS that contained 700,ug/ml of active 
G-418 and the surviving colonies were grown sequentially with increas- 
ing concentrations of methotrexate (MTX), according to [15]. Expres- 
sion of recombinant hLf from cells surviving in 300/~M MTX was 
carried out in DME/F12 with l% Ultroser G [15]. 
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2.4. Purification and analysis of recombinant protein 
Recombinant hLf was purified from DME/F12U by ion exchange 
chromatography. Medium was first centrifuged at3,000 x g for 15 min 
to eliminate cells in suspension and passed through a SP-Sepharose 
Fast Flow column equilibrated with 0.2 M sodium acetate, hLf was 
eluted with a salt gradient from 0 to 1 M NaCI in 0.2 M sodium acetate. 
The presence of recombinant hLf in eluted fractions was assessed by 
E LISA [16]. Positive fractions were pooled, concentrated, dialyzed and 
stored at -20°C. The purity of recombinant hLfwas checked by SDS- 
PAGE. 
2.5. Release and isolation of oligosaccharides 
Oligosaccharides from recombinant hLf were released by hydrazinol- 
ysis using the GlycoPrep 1000 apparatus (Oxford GlycoSystems) [17]. 
Hydrazinolysis of2 mg of recombinant glycoprotein was automatically 
processed with controlled conditions of temperature and time under an 
argon atmosphere. After removing excess hydrazine, N-acetylation was 
achieved by addition of acetic anhydride in a saturated solution of 
NaHCO3. Sodium ions and peptide material were removed from the 
sample by passage through a column of Dowex AG50 x 12. The ace- 
tohydrazone glycan derivatives were converted to unreduced glycans 
by addition of 1 mM copper acetate for 30 rain at 27°C [18]. After 
passage through amixed bed column of Chelex 100/Dowex AG50 x 12, 
the oligosaccharides were collected, concentrated and purified on a 
BioGel P2 column (12 x 60 cm). Elution was carried out with distilled 
water. The oligosaccharide fraction was stained with the orcinol-sulfu- 
tic reagent spray on TLC plates and freeze-dried for further analysis. 
2.6. Carbohydrate composition 
Monosaccharide molar ratios and percentage composition of total 
neutral sugars, hexosamines and sialic acids were determined after 
methanolysis, re-N-acetylation [19] and GLC of the trimethylsilylated 
methyl glycosides [20] on a capillary CP SIL 5CB column 
(0.2 mmx 25 m). 
2. 7. 400-MHz IH-NMR Spectroscopy 
For the 'H-NMR spectroscopic analysis, the oligosaccharides were 
repeatedly exchanged in DzO at room temperature and at pH 7 with 
intermediate lyophilization [21] and the 400-MHz ~H-NMR spectra 
were recorded on a Brfiker AM 400-WB spectrometer. 
3. Results 
3.1. Cloning, expression and purification of recombinant hLf  
A human mammary gland cDNA library was screened as 
previously described [12], using a 25-base oligonucleotide com- 
plementary to the 5' coding sequence of the hLf cDNA as a 
probe. The cDNA of a positive clone was sequenced and found 
to consist of the coding sequence of hLf cDNA (from nucleo- 
tide 287 to the 3' poly-A tail [12]). As detailed in section 2, after 
cloning the full-length 2.3 kb cDNA into pNUT, the resulting 
pNUT-hLf plasmid was used together with pcDNAI-neo to 
transfect BHK cells. The 300/~M MTX-resistant cells clones 
were induced with zinc and the amount of lactoferrin in the 
culture media ranged approximately from 5 to 15 mg. Purifica- 
tion of hLf by cation-exchange chromatography led to the 
N 6' 5' 
obtention of more than 7 mg protein/liter of culture medium. 
Recombinant hLf was visualized as a single protein band of 80 
kDa by SDS-PAGE (data not shown). 
3.2. Carbohydrate composition 
The carbohydrate moiety representing 6.0% of the glycopro- 
tein, consisted of 3.3% neutral sugars, 1.9% hexosamines and 
0.8% sialic acids. These values were similar to those of milk hLf 
[4]. The sugars were identified as galactose, fucose, mannose, 
glucosamine and neuraminic acid by GLC of their trimethylsi- 
lyl derivatives. The molar ratios of these monosaccharides were 
similar to those estimated in the oligosaccharides released after 
hydrazinolysis (Table 1). Compared to milk hLf, carbohydrate 
compositions of recombinant hLf and of the oligosaccharides 
were characterized by a lower content of fucose and neuraminic 
acid, suggesting both incomplete fucosylation and sialylation 
of the glycans. 
3.3. Determination of glycan primary structure 
The oligosaccharides from recombinant lactoferrin were re- 
leased by hydrazinolysis and submitted to 400-MHz 1H-NMR 
spectroscopy. The procedure used allowed the release of the 
oligosaccharides from a small amount of lactoferrin (2 mg) with 
a good yield (75%). From the IH-NMR spectrum data (Table 
2), the N-acetyllactosaminic type of the purified oligosac- 
charides can be asserted. The anomeric proton of the GlcNAc-1 
(8 H-1~ -- 5.181) proved the completeness of the hydrazinolysis 
reaction [22]. The presence of the Man-4 and Man-4' anomeric 
protons (8 = 5.116 and 8 = 4.920, respectively) and also the H-2 
of the three mannose residues (8 H-2 Man-3 = 4.250, 8 H-2 
Man-4 -- 4.192, 8 H-2 Man-4' -- 4.110) are in favour of a bian- 
tennary structure with two fully c~-2,3-sialylated branches (ap- 
proximately 80% of total glycans, calculated on the basis of 
NMR peak integration and carbohydrate composition) and 
partially c~-2,3-sialylated branches (20% of total glycans) [21]. 
Asialo Gal-6 and Gal-6' H-1 are observed at 8 = 4.465 and 
8--4.470 ppm, respectively. The ~-2,3-1inkage of NeuAc is 
clearly verified by the chemical shift observed for the NeuAc 
H-3ax and H-3eq atom resonances [21] (Table 2). The spec- 
trum also evidences the presence of c~-1,6 Fuc linked to 
GlcNAc-1, but only for about 70% of the total glycan chains 
[21], in accordance with the carbohydrate composition. The 
identified oligosaccharides have the structures indicated in 
Fig. 1. 
4. Discussion 
Previous reports dealt with the obtention of functional re- 
combinant hLf and of its N-terminal half in BHK cells with the 
4 ' 
[NeuAc (~2-3) ] Gal (~I-4) GIcNAc (~i-2) Man (~I-6) [Fuc (~I-6) ] o-I 
o-1 \ i 
Man ([31-4) GIcNAc (~I-4) GIcNAc 
/ 
N 6 5 4 /3  
2 1 
[NeuAc (u2-3) ] Gal (~I-4) GIcNAc (~I-2) Man (ul-3) 
o-1 
Fig. 1. Primary structures of the oligosaccharides isolated from recombinant hLf in BHK cells. 
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Table 1 
Molar carbohydrate compositions of recombinant hLf compared to 
milk hLf and of the oligosaccharides released by hydrazinolysis 
Fuc Gal Man a GIcNAc NeuAc 
Milk hLf 1.3 2.1 3.0 4.0 1.8 
Recombinant 
hLf 0.8 1.9 3.0 3.6 1.6 
Released 
oligo- 
saccharides 0.7 2.0 3.0 3.5 1.6 
a Molar ratios were calculated on the basis of three Man residues. 
expression vector pNUT [10,11]. In the present study, we have 
cloned a full-length cDNA of human lactoferrin and expressed 
it in BHK cells with a protein yield in the culture medium of 
5-15 mg/1, similar to that previously reported [10]. On the basis 
of a molecular weight of 82,400 Da for hLf [23] and of the 
percentage carbohydrate composition of the recombinant pro- 
tein (6.0%), we can assume that the recombinant hLf possesses 
two glycans of about 2,400 daltons, as do milk and leucocyte 
hLfs [4,5]. By ~H-NMR spectroscopy, the two glycans of re- 
combinant hLf have been identified as biantennary structures 
of the sialylated N-acetyllactosaminic type with one or two 
~-2,3-1inked NeuAc residues and the partial presence of an 
~-1,6 fucose residue linked to GIcNAc-1. 
It is thus worthy of note that, despite of fucosylation and 
sialylation features which are specific to the cell line used [24], 
the glycosylation of recombinant hLf in BHK cells occurs at 
59 
the same degree of complexity as that of naturally-occurring 
hLfs [4,5]. A number of other glycoproteins, including serum 
transferrin [15,25], have been successfully produced at a high- 
expression level in BHK cells. The glycosylation of some re- 
combinant proteins expressed in BHK cells, for instance human 
erythropoietin (EPO) [26], has been extensively studied. Human 
recombinant EPO contains a very complex mixture of tetra-, 
tri- and biantennary glycans of the N-acetyllactosaminic type, 
sometimes with N-acetyllactosamine repeats [26]. Interestingly, 
sugar chains of recombinant EPO were found to be very similar 
to those of human urinary EPO, except for the sialyl linkage 
[27]. In the particular case of recombinant human serum trans- 
ferrin produced in BHK cells, electrospray mass analysis of the 
recombinant protein suggested the existence of a complex pat- 
tern of bi- and triantennary glycans [15]. Such a microhetero- 
geneity was also evidenced for native human serum transferrin 
[28,29]. These observations indicate that, whether glycosylation 
of a recombinant protein depends on the host cell type, the 
culture environment and the method of cell culture [30], it also 
depends to some degree on the structure of the protein moiety. 
Differences between the glycans of recombinant hLf and 
those of hLf from milk or from leucocytes concern the nature 
of the linkage between NeuAc and Gal (~-2,3 for the recombi- 
nant protein, instead of c~-2,6 for the native lactoferrins), as well 
as the fucosylation patterns. These differences are relevant o 
the fact that BHK cells naturally lack the capability of ~-2,6 
sialylation and ~-1,3 fucosylation of Gal fl-1,4 GIcNAc-R mo- 
tifs on N-glycans [24]. 
Table 2 
~H chemical shifts of structural reporter groups of constituent monosaccharides for oligosaccharides from recombinant hLf 
Reporter group Residue Chemical shifts 
H-I GIcNAc-lc~ 5.181 5.181 5.181 
Fuc(l-6)c~,fl 4.89 4.89 4.89 
GlcNAc-2 
Man-3 - - 
Man-4 5.116 5.116 5.116 
Man-4' 4.920 4.920 4.920 
GlcNAc-5 4.58 - 4.58 
GlcNAc-5' - 4.58 4.58 
Gal-6 4.53 4.465 4.53 
Gal-6' 4.470 4.53 4.53 
H-2 Man-3 4.250 4.250 4.250 
Man-4 4.192 4.192 4.192 
Man-4' 4.11 4.11 4.11 
H-3 Gal-6,6' 4.11~4.12 
H-3ax NeuAc 1.801 1.801 1.801 
H-3eq NeuAc 2.758 2.758 2.758 
H-6 Fuc(1-6)~ 1.210 1.210 1.210 
/~ 1.22 1.22 1.22 
NAc GIcNAc-1 2.04 2.04 2.04 
GlcNAc-2 2.094 2.094 2.094 
GlcNAc-5 2.048 2.048 
GIcNAc-5' 2.044 2.044 
NeuAc 2.030 2.030 2.030 
Compounds are represented byschematic structures according to [21]. u, GIcNAc; ©, Man; e, Gal; A, Neu5Ac; [], Fuc. 
relative to sodium 4-4-dimethyl-4-silapentane-sulphonate but wer  actually measured by reference to internal acetone 
an accuracy of more or less than 0.002 ppm. 
Chemical shifts (8) are given 
in D:O: 8 = 2.225 ppm with 
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It is now well admitted that glycans have effects on protein 
solubility and stability, immunogenicity, pharmacokinetics and 
biological activities [30]. In the case of lactoferrin, in vitro 
experiments, however, have failed to demonstrate the role of 
glycans in iron binding and release [31]. Nevertheless, the gly- 
can moiety was shown to stabilize the iron-binding site of the 
30 kDa N-tryptic fragment and the N-terminal domain II of 
milk hLf [32]. Concerning human serum transferrin, a study 
reported that the non-glycosylated protein bound to HeLa $3 
cells with the same avidity and to the same extent as the glyco- 
sylated protein [15]. For many glycoproteins, full glycosylation 
equates with full biological activity [30], but there are several 
instances where the glycosylation status has no major impact 
on the biological efficacy of a protein in vitro. For example, 
although desialylated human EPO shows a thousand-fold re- 
duction in specific activity in vivo compared to its native tbrm, 
there is little effect in vitro. [33]. Since no drastic change in the 
number of sialic acid residues and in the global volume of the 
carbohydrate chains at the surface of the protein occurred, it 
is likely that the overall physicochemical properties of recombi- 
nant hLf are not altered compared to native hLfs. However, 
possible alterations of the in vivo biological activity, the clear- 
ance and distribution of recombinant hLf in the organism may 
be induced by the c~-2,3 linkage of NeuAc and the lack of c~-1,3 
Fuc. It can be thus postulated that the masking ability and 
antigenicity of ~-2,3 NeuAc is different From c~-2,6 NeuAc and 
can affect the immunogenicity of the protein. Moreover, recog- 
nition systems uch as the selectin ELAM-1 expressed on the 
vascular endothelium are able to trap cc-2,3 NeuAc-containing 
glycoproteins [34]. Finally, the recognition of the c~-1,3 Fuc 
residue present on milk hLf glycans by a specific lectinic recep- 
tor on rat hepatic ells has been reported [7,8]. The lack ofc~-l,3 
fucosylation and the partial lack of c~-1,6 Fuc in recombinant 
hLf may also influence the clearance and the distribution of the 
recombinant protein in the organism. 
From this study, we can conclude that under our cell culture 
conditions, the glycosylation of recombinant hLfis close to that 
of homologous milk and leucocyte hLfs. Recombinant hLf 
glycans, however, possess specific features which have to be 
taken into account for the interpretation f in vitro and in vivo 
biological experiments. 
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